In a report released yesterday, Evan Seigerman from Credit Suisse maintained a Buy rating on Satsuma Pharmaceuticals (STSA – Research Report), with a price target of $32.00. The company’s shares closed last Wednesday at $20.28. According to TipRanks.com, Seigerman is